Case number 2016-2555
Eli Lilly and Company v. Perrigo Company > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | ELI LILLY AND COMPANY v. PERRIGO COMPANY [OPINION] [nonprecedential] (0) |
| Jan 3, 2018 | 107 | Mandate issued to the United States District Court for the Southern District of Indiana. Service as of this date by Clerk of Court. [486878] [16-2555, 16-2614] [SJ] [Entered: 01/03/2018 08:55 AM] (1) |
| Nov 22, 2017 | 106 | OPINION and JUDGMENT filed. The judgment or decision is: Affirmed. (Nonprecedential Opinion). (For the Court: Chen,Circuit Judge; Plager,Circuit Judge and Hughes,Circuit Judge). [477707] [16-2555, 16-2614] [JAB] [Entered: 11/22/2017 09:47 AM] (12) |
| Oct 5, 2017 | 105 | Submitted after ORAL ARGUMENT by Charles E. Lipsey for Eli Lilly and Company, Eli Lilly Export S.A. and Acrux DDS Pty Ltd., Michael Keenan Nutter for Actavis Laboratories UT, Inc., Lupin Ltd. and Lupin Pharmaceuticals, Inc., William A. Rakoczy for Perrigo Company and Perrigo Israel Pharmaceuticals Ltd. and John T. Battaglia for Amneal Pharmaceuticals LLC. Panel: Judge: Chen , Judge: Plager , Judge: Hughes. [465782] [JAB] [Entered: 10/05/2017 10:44 AM] (0) |
| Oct 2, 2017 | 104 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Appellants Acrux DDS Pty Ltd., Eli Lilly Export S.A. and Eli Lilly and Company. Service: 10/02/2017 by email. [464901] [Charles Lipsey] [Entered: 10/02/2017 05:27 PM] (2) |
| Sep 29, 2017 | 103 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Cross-Appellant Amneal Pharmaceuticals LLC. Service: 09/29/2017 by email. [464504] [John Battaglia] [Entered: 09/29/2017 05:47 PM] (52) |
| Sep 18, 2017 | 100 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:calendar response Docket No. [96], ERROR: Counsel for appellees Lupin Ltd. and Lupin Pharmaceuticals, Inc. submitted a response to the oral argument order designating 0 minutes for argument and 0 minutes for rebuttal. CORRECTION: If a party wishes to waive oral argument, please select the appropriate form of waiver from the drop-down menu when submitting the response. If one attorney is arguing on behalf of multiple parties, he/she must submit a response that indicates all parties represented at argument. Please promptly submit a corrected response. [461560] [JAB] [Entered: 09/18/2017 07:54 AM] (0) |
| Sep 18, 2017 | 101 | Clerk's Note to the File: Oral argument will be held in Courtroom 203, rather than Courtroom 402. [461776] [JAB] [Entered: 09/18/2017 02:41 PM] (0) |
| Sep 18, 2017 | 102 | AMENDED Response to oral argument order from the Appellees Actavis Laboratories UT, Inc., Lupin Ltd. and Lupin Pharmaceuticals, Inc.. designating Michael Keenan Nutter as arguing attorney. Designated time for argument: 5 minutes. Designated time for rebuttal: 0 minutes. Service of other counsel by Notice of Docket Activity from this entry. [461861] [Michael Nutter] [Entered: 09/18/2017 04:40 PM] (0) |
| Sep 15, 2017 | 94 | ORDER filed denying [93] motion to seek more time for argument filed by Amneal Pharmaceuticals LLC. By: Merits Panel (Per Curiam). Service as of this date by Clerk of Court. [461299] [JAB] [Entered: 09/15/2017 12:39 PM] (2) |
| Sep 15, 2017 | 95 | Response to oral argument order from the Appellants Acrux DDS Pty Ltd., Eli Lilly Export S.A. and Eli Lilly and Company. designating Charles E. Lipsey as arguing attorney. Designated time for argument: 12 minutes. Designated time for rebuttal: 3 minutes. Service of other counsel by Notice of Docket Activity from this entry. [461523] [Charles Lipsey] [Entered: 09/15/2017 04:36 PM] (0) |
| Sep 15, 2017 | 96 | Response to oral argument order from the Appellees Lupin Ltd. and Lupin Pharmaceuticals, Inc.. designating Actavis' counsel, who will be requesting at least 5 minutes of time as arguing attorney. Designated time for argument: 0 minutes. Designated time for rebuttal: 0 minutes. Service of other counsel by Notice of Docket Activity from this entry. [461527] [Keith Parr] [Entered: 09/15/2017 04:40 PM] (0) |
| Sep 15, 2017 | 97 | Response to oral argument order from the Appellees Perrigo Company and Perrigo Israel Pharmaceuticals Ltd.. designating William A. Rakoczy as arguing attorney. Designated time for argument: 5 minutes. Designated time for rebuttal: 0 minutes. Service of other counsel by Notice of Docket Activity from this entry. [461530] [William Rakoczy] [Entered: 09/15/2017 04:51 PM] (0) |
| Sep 15, 2017 | 98 | Response to oral argument order from the Cross-Appellant Amneal Pharmaceuticals LLC. designating John T. Battaglia as arguing attorney. Designated time for argument: 4 minutes. Designated time for rebuttal: 1 minutes. Service of other counsel by Notice of Docket Activity from this entry. [461535] [John Battaglia] [Entered: 09/15/2017 04:55 PM] (0) |
| Sep 15, 2017 | 99 | Response to oral argument order from the Appellee Actavis Laboratories UT, Inc.. designating Michael Keenan Nutter as arguing attorney. Designated time for argument: 5 minutes. Designated time for rebuttal: 0 minutes. Service of other counsel by Notice of Docket Activity from this entry. [461541] [Michael Nutter] [Entered: 09/15/2017 05:08 PM] (0) |
| Sep 12, 2017 | 93 | CORRECTED ENTRY: MOTION of Cross-Appellant Amneal Pharmaceuticals LLC for additional time at oral argument. Any response is due within 10 days of service [Consent: unopposed]. Service: 09/12/2017 by email. [460387]--[Edited 09/12/2017 by clerk - Reason: to add correct relief] [John Battaglia] [Entered: 09/12/2017 12:32 PM] (8) |
| Aug 21, 2017 | 92 | NOTICE OF CALENDARING. Panel: 1710N. Case scheduled Oct 05, 2017 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, N.W. Washington, DC 20439), Courtroom 402. Response to oral argument order due: 09/15/2017. Arguing counsel is required to check-in at the Clerk's Office, 4th Floor, Room 401, between 8:30 a.m. and 9:30 a.m. on the day of argument. Please review the Oral Argument Order. [455396] [JAB] [Entered: 08/21/2017 01:24 PM] (0) |
| Apr 26, 2017 | 91 | Notice from Cross-Appellant Amneal Pharmaceuticals LLC regarding conflicts with oral argument (July 10-14, 2017 and October 3-4, 2017). Service: 04/26/2017 by email. [427300] [John Battaglia] [Entered: 04/26/2017 02:10 PM] (1) |
| Apr 25, 2017 | 90 | Notice from Appellee Actavis Laboratories UT, Inc. regarding conflicts with oral argument (September 5-8, 2017). Service: 04/25/2017 by email. [427078] [Geoffrey Eaton] [Entered: 04/25/2017 05:47 PM] (2) |
| Apr 24, 2017 | 89 | Notice from Appellants Acrux DDS Pty Ltd., Eli Lilly Export S.A. and Eli Lilly and Company regarding conflicts with oral argument (July 10-14, 2017). Service: 04/24/2017 by email. [426529] [Charles Lipsey] [Entered: 04/24/2017 11:29 AM] (1) |
| Apr 21, 2017 | 88 | Notice from Appellees Perrigo Company and Perrigo Israel Pharmaceuticals Ltd. regarding conflicts with oral argument (June 20-21; August 1, 4, 10, and 21-31; and September 1-15 and 26, 2017). Service: 04/21/2017 by email. [426378] [William Rakoczy] [Entered: 04/21/2017 05:14 PM] (2) |
| Apr 20, 2017 | 87 | 6 paper copies of the Joint Appendix in 4 Volumes [85] received from Appellants Acrux DDS Pty Ltd., Eli Lilly Export S.A. and Eli Lilly and Company. [426039] [JCP] [Entered: 04/21/2017 07:15 AM] (0) |
| Apr 19, 2017 | 86 | Pursuant to Practice Note 34, counsel should advise the clerk of court of scheduling conflicts for the next three court weeks (July 2017, August 2017, September 2017), or thereafter. When filing the notice of conflicts, counsel should docket the Notice Regarding Conflicts with Argument Dates event, which is found in the Calendar event category. The notice of conflict with oral argument is due on or before 04/26/2017. [425612] [JCA] [Entered: 04/19/2017 03:11 PM] (0) |
| Apr 17, 2017 | 78 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellees Perrigo Company and Perrigo Israel Pharmaceuticals Ltd.. Service: 04/17/2017 by email. [424591] [Alice Riechers] [Entered: 04/17/2017 11:00 AM] (2) |
| Apr 17, 2017 | 79 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellees Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 04/17/2017 by email. [424777] [Keith Parr] [Entered: 04/17/2017 03:23 PM] (3) |
| Apr 17, 2017 | 80 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellee Actavis Laboratories UT, Inc.. Service: 04/17/2017 by email. [424833] [Kurt Mathas] [Entered: 04/17/2017 04:55 PM] (3) |
| Apr 17, 2017 | 81 | TENDERED from Appellants Acrux DDS Pty Ltd., Eli Lilly Export S.A. and Eli Lilly and Company. Title: JOINT APPENDIX. Service: 04/17/2017 by email. [424836] [Charles Lipsey] [Entered: 04/17/2017 05:10 PM] (2365) |
| Apr 17, 2017 | 82 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellants Acrux DDS Pty Ltd., Eli Lilly Export S.A. and Eli Lilly and Company. Service: 04/17/2017 by email. [424838] [Charles Lipsey] [Entered: 04/17/2017 05:12 PM] (3) |
| Apr 17, 2017 | 83 | Statement of Compliance with Fed. Cir. R. 33 for Appellants Acrux DDS Pty Ltd., Eli Lilly Export S.A., Eli Lilly and Company, Appellees Actavis Laboratories UT, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., Perrigo Company, Perrigo Israel Pharmaceuticals Ltd. and Cross-Appellant Amneal Pharmaceuticals LLC. Service: 04/17/2017 by email. [424839] [Charles Lipsey] [Entered: 04/17/2017 05:14 PM] (4) |
| Apr 17, 2017 | 84 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Cross-Appellant Amneal Pharmaceuticals LLC. Service: 04/17/2017 by email. [424842] [John Battaglia] [Entered: 04/17/2017 05:29 PM] (2) |
| Apr 17, 2017 | 85 | APPENDIX FILED for Acrux DDS Pty Ltd., Eli Lilly Export S.A. and Eli Lilly and Company [81]. Number of Pages: 2365. Service: 04/17/2017 by email. The paper copies of the brief should be received by the court on or before 04/25/2017. [424963] [JCA] [Entered: 04/18/2017 09:35 AM] (2365) |
| Apr 11, 2017 | 77 | 6 paper copies of the Reply Brief [76] received from Cross-Appellant Amneal Pharmaceuticals LLC. [423467] [KW] [Entered: 04/12/2017 01:45 PM] (0) |
| Apr 10, 2017 | 75 | TENDERED from Cross-Appellant Amneal Pharmaceuticals LLC. Title: REPLY BRIEF. Service: 04/10/2017 by email. [423005] [John Battaglia] [Entered: 04/10/2017 11:21 PM] (47) |
| Apr 10, 2017 | 76 | REPLY BRIEF FILED for Cross-Appellant Amneal Pharmaceuticals LLC [75]. Number of Pages: 35. Service: 04/10/2017 by email. The paper copies of the brief should be received by the court on or before 04/18/2017. Appendix is due 04/17/2017. [423089] [JCA] [Entered: 04/11/2017 11:33 AM] (47) |
| Mar 17, 2017 | 73 | MOTION of Cross-Appellant Amneal Pharmaceuticals LLC to extend the time to 04/10/2017 at 11:59 pm to file the cross-appellant's reply brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 03/17/2017 by email. [416548] [John Battaglia] [Entered: 03/17/2017 11:25 AM] (8) |
| Mar 17, 2017 | 74 | **TEXT ONLY** ORDER granting motion to extend time to file cross-appellant's reply brief [73] filed by Cross-Appellant Amneal Pharmaceuticals LLC. Cross-Appellant's reply brief due 04/10/2017. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [416680] [JCA] [Entered: 03/17/2017 03:43 PM] (0) |
| Mar 16, 2017 | 72 | 6 paper copies of the Reply Brief [71] received from Appellants Acrux DDS Pty Ltd., Eli Lilly Export S.A. and Eli Lilly and Company. [416257] [KW] [Entered: 03/16/2017 02:27 PM] (0) |
| Mar 13, 2017 | 70 | TENDERED from Appellants Acrux DDS Pty Ltd., Eli Lilly Export S.A. and Eli Lilly and Company. Title: RESPONSE BRIEF. Service: 03/13/2017 by email. [414968] [Charles Lipsey] [Entered: 03/13/2017 03:44 PM] (65) |
| Mar 13, 2017 | 71 | REPLY BRIEF FILED for Appellants Acrux DDS Pty Ltd., Eli Lilly Export S.A. and Eli Lilly and Company [70]. Number of Pages: 51. Service: 03/13/2017 by email. The paper copies of the brief should be received by the court on or before 03/21/2017. Cross-Appellant's reply brief is due 03/27/2017. [415174] [JCA] [Entered: 03/14/2017 10:02 AM] (65) |
| Mar 2, 2017 | 68 | Amended Certificate of Interest for the Appellants Acrux DDS Pty Ltd., Eli Lilly Export S.A. and Eli Lilly and Company. Service: 03/02/2017 by email. [411954] [Alissa Lipton] [Entered: 03/02/2017 12:15 PM] (3) |
| Mar 2, 2017 | 69 | Letter from Appellants Acrux DDS Pty Ltd., Eli Lilly Export S.A., Eli Lilly and Company and Appellee Actavis Laboratories UT, Inc. notifying the court that issues relating to U.S. Patent 8,071,075 are no longer in dispute. Service: 03/02/2017 by email. [411975] [Alissa Lipton] [Entered: 03/02/2017 01:22 PM] (6) |
| Feb 3, 2017 | 66 | 6 paper copies of the Corrected Response Brief [65] received from Appellees Actavis Laboratories UT, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc. and Cross-Appellant Amneal Pharmaceuticals LLC. [404623] [KW] [Entered: 02/03/2017 02:32 PM] (0) |
| Feb 3, 2017 | 67 | 6 paper copies of the Response Brief [62] received from Appellees Perrigo Company and Perrigo Israel Pharmaceuticals Ltd. [404633] [KW] [Entered: 02/03/2017 02:45 PM] (0) |
| Feb 1, 2017 | 63 | Notice of Correction to the Brief Doc No. [61] for Appellees Actavis Laboratories UT, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc. and Cross-Appellant Amneal Pharmaceuticals LLC. Service: 02/01/2017 by email. [403768] [Geoffrey Eaton] [Entered: 02/01/2017 12:49 PM] (2) |
| Feb 1, 2017 | 64 | TENDERED from Appellees Actavis Laboratories UT, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc. and Cross-Appellant Amneal Pharmaceuticals LLC. Title: CORRECTED RESPONSE BRIEF. Service: 02/01/2017 by email. [403769] [Geoffrey Eaton] [Entered: 02/01/2017 12:50 PM] (71) |
| Feb 1, 2017 | 65 | CORRECTED BRIEF FILED for Appellees Actavis Laboratories UT, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc. and Cross-Appellant Amneal Pharmaceuticals LLC [64]. Number of Pages: 58. Service: 02/01/2017 by email. The paper copies of the brief should be received by the court on or before 02/08/2017. Appellant's reply brief is due 03/13/2017. [403841] [JCA] [Entered: 02/01/2017 02:45 PM] (71) |
| Jan 30, 2017 | 59 | Entry of appearance for Geoffrey P. Eaton as of counsel for Appellee Actavis Laboratories UT, Inc.. Service: 01/30/2017 by email. [403003] [Geoffrey Eaton] [Entered: 01/30/2017 12:24 PM] (2) |
| Jan 30, 2017 | 60 | TENDERED from Appellees Perrigo Company and Perrigo Israel Pharmaceuticals Ltd.. Title: RESPONSE BRIEF. Service: 01/30/2017 by email. [403190] [William Rakoczy] [Entered: 01/30/2017 04:19 PM] (78) |
| Jan 30, 2017 | 61 | TENDERED from Appellees Actavis Laboratories UT, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc. and Cross-Appellant Amneal Pharmaceuticals LLC. Title: RESPONSE BRIEF. Service: 01/30/2017 by email. [403202]. This brief has been replaced. See Doc No.[65] [Geoffrey Eaton] [Entered: 01/30/2017 04:43 PM] (0) |
| Jan 30, 2017 | 62 | BRIEF FILED for Appellees Perrigo Company and Perrigo Israel Pharmaceuticals Ltd. [60]. Number of Pages: 64. Service: 01/30/2017 by email. The paper copies of the brief should be received by the court on or before 02/07/2017. Appellant's reply brief is due 03/13/2017. [403522] [JCA] [Entered: 01/31/2017 04:09 PM] (78) |
| Dec 22, 2016 | 58 | 6 paper copies of the Opening Response Brief [56] received from Cross-Appellant Amneal Pharmaceuticals LLC. [393572] [JCP] [Entered: 12/22/2016 12:30 PM] (0) |
| Dec 20, 2016 | 57 | Clerk's Note to the File: Pursuant to the modified briefing schedule used in appeals with appellants, appellees, and cross-appellants, the briefs of appellees Actavis Laboratories UT, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., Perrigo Company and Perrigo Israel Pharmaceuticals Ltd. are due on 1/30/17 [392585] [JCA] [Entered: 12/20/2016 11:09 AM] (0) |
| Dec 19, 2016 | 55 | TENDERED from Cross-Appellant Amneal Pharmaceuticals LLC. Title: RESPONSE BRIEF. Service: 12/19/2016 by email. [392457] [John Battaglia] [Entered: 12/19/2016 08:38 PM] (95) |
| Dec 19, 2016 | 56 | BRIEF FILED for Cross-Appellant Amneal Pharmaceuticals LLC [55]. Number of Pages: 79. Service: 12/19/2016 by email. The paper copies of the brief should be received by the court on or before 12/27/2016. [392582] [JCA] [Entered: 12/20/2016 11:05 AM] (95) |
| Dec 16, 2016 | 54 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.4(a)and Fed. Cir. R. 47.3 to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [391703] [JCA] [Entered: 12/16/2016 10:22 AM] (0) |
| Nov 16, 2016 | 53 | Clerk's Note to the File: The parties are advised that a slight modification has been made to the order of the parties in the official caption. Any further filings and briefs should comply with the revised official caption. The change was made after the tendering and filing of appellants’ opening brief. Appellants do not need to file a corrected brief. [383458] [JCA] [Entered: 11/16/2016 08:37 AM] (0) |
| Nov 15, 2016 | 52 | 6 paper copies of the Opening Brief [51] received from Appellants Acrux DDS Pty Ltd., Eli Lilly Export S.A. and Eli Lilly and Company. [383212] [KW] [Entered: 11/15/2016 01:58 PM] (0) |
| Nov 7, 2016 | 50 | TENDERED from Appellants Acrux DDS Pty Ltd., Eli Lilly Export S.A. and Eli Lilly and Company. Title: OPENING BRIEF. Service: 11/07/2016 by email. [381065] [Charles Lipsey] [Entered: 11/07/2016 05:48 PM] (345) |
| Nov 7, 2016 | 51 | BRIEF FILED for Appellants Acrux DDS Pty Ltd., Eli Lilly Export S.A. and Eli Lilly and Company [50]. Number of Pages: 59. Service: 11/07/2016 by email. The paper copies of the brief should be received by the court on or before 11/15/2016. Cross-Appellant Amneal Pharmaceuticals LLC brief is due 12/19/2016. [382056] [JCA] [Entered: 11/10/2016 02:41 PM] (345) |
| Oct 18, 2016 | 48 | **TEXT ONLY** ORDER granting motion to extend time to file appellant/petitioner principal brief [47] filed by Appellants Eli Lilly and Company, Eli Lilly Export S.A. and Acrux DDS Pty Ltd. Brief due 11/07/2016. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [375166] [JCA] [Entered: 10/18/2016 08:59 AM] (0) |
| Oct 18, 2016 | 49 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: Notice regarding the ECF account of Mr. Anthony James Fitzpatrick, Esq. for Amneal Pharmaceuticals LLC. The e-mail address, (kaangelo@duanemorris.com), associated with your CM/ECF account has generated a delivery failure notice. Counsel should promptly report a change in contact information with the Pacer Service Center (see Fed. Cir. R. 47.3(c)(1). [375501] [PMM] [Entered: 10/18/2016 03:11 PM] (0) |
| Oct 17, 2016 | 47 | MOTION of Appellants Acrux DDS Pty Ltd., Eli Lilly Export S.A. and Eli Lilly and Company to extend the time to 11/07/2016 at 11:59 pm to file the appellant/petitioner's principal brief. Response/Opposition is due 10/31/2016 [Consent: unopposed]. Service: 10/17/2016 by email. [375041] [Alissa Lipton] [Entered: 10/17/2016 04:17 PM] (7) |
| Oct 14, 2016 | 46 | Amended Certificate of Interest for the Cross-Appellant Amneal Pharmaceuticals LLC. Service: 10/14/2016 by email. [374200] [John Battaglia] [Entered: 10/14/2016 11:24 AM] (3) |
| Oct 13, 2016 | 44 | Amended Entry of appearance for Anthony J. Fitzpatrick as of counsel for Cross-Appellant Amneal Pharmaceuticals LLC. Service: 10/13/2016 by email. [374044] [John Battaglia] [Entered: 10/13/2016 08:10 PM] (2) |
| Oct 13, 2016 | 45 | Amended Entry of appearance for John Battaglia as principal counsel for Cross-Appellant Amneal Pharmaceuticals LLC. Service: 10/13/2016 by email. [374045] [John Battaglia] [Entered: 10/13/2016 08:12 PM] (2) |
| Sep 29, 2016 | 41 | Entry of appearance for John Battaglia as of counsel for Cross-Appellant Amneal Pharmaceuticals LLC. Service: 09/29/2016 by email. [370223] [John Battaglia] [Entered: 09/29/2016 02:22 PM] (2) |
| Sep 29, 2016 | 42 | Entry of appearance for R. William Sigler as of counsel for Cross-Appellant Amneal Pharmaceuticals LLC. Service: 09/29/2016 by email. [370229] [R. Sigler] [Entered: 09/29/2016 02:29 PM] (2) |
| Sep 29, 2016 | 43 | Entry of appearance for Joseph Edell as of counsel for Cross-Appellant Amneal Pharmaceuticals LLC. Service: 09/29/2016 by email. [370230] [Joseph Edell] [Entered: 09/29/2016 02:30 PM] (2) |
| Sep 27, 2016 | 40 | Entry of appearance for Carolyn A. Alenci as of counsel for Cross-Appellant Amneal Pharmaceuticals LLC. Service: 09/27/2016 by email. [369690] [Anthony Fitzpatrick] [Entered: 09/27/2016 04:26 PM] (2) |
| Sep 21, 2016 | 39 | Entry of appearance for Lauren Lesko as of counsel for Appellees Perrigo Company and Perrigo Israel Pharmaceuticals Ltd.. Service: 09/21/2016 by email. [368104] [Lauren Lesko] [Entered: 09/21/2016 12:27 PM] (2) |
| Sep 12, 2016 | 38 | Entry of appearance for Dan H. Hoang as of counsel for Appellee Actavis Laboratories UT, Inc.. Service: 09/12/2016 by email. [365871] [Dan Hoang] [Entered: 09/12/2016 03:17 PM] (2) |
| Sep 8, 2016 | 37 | Transcript Purchase Order Form from the United States District Court indicating that a transcript is already on file. Service: 09/08/2016 by clerk. [365174] [JCA] [Entered: 09/08/2016 12:23 PM] (2) |
| Sep 7, 2016 | 20 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:attorney entry of appearance Docket No. [19], ERROR: Vincent L. Capuano does not appear to have a CM/ECF account. CORRECTION: All counsel who intend to appear in this court must be registered for CM/ECF pursuant to FCR 25(a)(2). Once the CM/ECF account is created, the Entry of Appearance can be processed. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [364633] [JCA] [Entered: 09/07/2016 09:40 AM] (0) |
| Sep 7, 2016 | 21 | Entry of appearance for Christine J. Siwik as of counsel for Appellees Perrigo Company and Perrigo Israel Pharmaceuticals Ltd.. Service: 09/07/2016 by email. [364651] [Christine Siwik] [Entered: 09/07/2016 10:39 AM] (2) |
| Sep 7, 2016 | 22 | Entry of appearance for Gregory A. Duff as of counsel for Appellees Perrigo Company and Perrigo Israel Pharmaceuticals Ltd.. Service: 09/07/2016 by email. [364656] [Gregory Duff] [Entered: 09/07/2016 10:47 AM] (2) |
| Sep 7, 2016 | 23 | Entry of appearance for Michael K. Nutter as principal counsel for Appellee Actavis Laboratories UT, Inc.. Service: 09/07/2016 by email. [364727] [Michael Nutter] [Entered: 09/07/2016 01:21 PM] (2) |
| Sep 7, 2016 | 24 | Entry of appearance for Kurt A. Mathas as of counsel for Appellee Actavis Laboratories UT, Inc.. Service: 09/07/2016 by email. [364730] [Kurt Mathas] [Entered: 09/07/2016 01:25 PM] (2) |
| Sep 7, 2016 | 25 | Docketing Statement for the Appellee Actavis Laboratories UT, Inc.. Service: 09/07/2016 by email. [364733] [Kurt Mathas] [Entered: 09/07/2016 01:27 PM] (4) |
| Sep 7, 2016 | 26 | Certificate of Interest for the Appellee Actavis Laboratories UT, Inc.. Service: 09/07/2016 by email. [364734] [Kurt Mathas] [Entered: 09/07/2016 01:29 PM] (4) |
| Sep 7, 2016 | 27 | Note to file: The following cases are associated:16-2555 Lead with 16-2614 Cross-Appeal. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [364740] [16-2555, 16-2614] [JCA] [Entered: 09/07/2016 01:41 PM] (0) |
| Sep 7, 2016 | 28 | Entry of appearance for Charles E. Lipsey as principal counsel for Appellants Acrux DDS Pty Ltd., Eli Lilly Export S.A. and Eli Lilly and Company. Service: 09/07/2016 by email. [364920] [Charles Lipsey] [Entered: 09/07/2016 04:54 PM] (2) |
| Sep 7, 2016 | 29 | Certificate of Interest for the Appellants Acrux DDS Pty Ltd., Eli Lilly Export S.A. and Eli Lilly and Company. Service: 09/07/2016 by email. [364921] [Charles Lipsey] [Entered: 09/07/2016 04:55 PM] (3) |
| Sep 7, 2016 | 30 | Docketing Statement for the Appellants Acrux DDS Pty Ltd., Eli Lilly Export S.A. and Eli Lilly and Company. Service: 09/07/2016 by email. [364923] [Charles Lipsey] [Entered: 09/07/2016 04:57 PM] (3) |
| Sep 7, 2016 | 31 | Entry of appearance for L. Scott Burwell as of counsel for Appellants Acrux DDS Pty Ltd., Eli Lilly Export S.A. and Eli Lilly and Company. Service: 09/07/2016 by email. [364926] [Charles Lipsey] [Entered: 09/07/2016 04:58 PM] (2) |
| Sep 7, 2016 | 32 | Entry of appearance for Manisha A. Desai as of counsel for Appellants Eli Lilly Export S.A. and Eli Lilly and Company. Service: 09/07/2016 by email. [364928] [Charles Lipsey] [Entered: 09/07/2016 05:00 PM] (2) |
| Sep 7, 2016 | 33 | Entry of appearance for Howard W. Levine as of counsel for Appellants Acrux DDS Pty Ltd., Eli Lilly Export S.A. and Eli Lilly and Company. Service: 09/07/2016 by email. [364929] [Charles Lipsey] [Entered: 09/07/2016 05:01 PM] (2) |
| Sep 7, 2016 | 34 | Entry of appearance for Laura P. Masurovsky as of counsel for Appellants Acrux DDS Pty Ltd., Eli Lilly Export S.A. and Eli Lilly and Company. Service: 09/07/2016 by email. [364931] [Charles Lipsey] [Entered: 09/07/2016 05:02 PM] (2) |
| Sep 7, 2016 | 35 | Entry of appearance for Alissa K. Lipton as of counsel for Appellants Acrux DDS Pty Ltd., Eli Lilly Export S.A. and Eli Lilly and Company. Service: 09/07/2016 by email. [364933] [Charles Lipsey] [Entered: 09/07/2016 05:03 PM] (2) |
| Sep 7, 2016 | 36 | Entry of appearance for Jennifer S. Swan as of counsel for Appellants Acrux DDS Pty Ltd., Eli Lilly Export S.A. and Eli Lilly and Company. Service: 09/07/2016 by email. [364934] [Charles Lipsey] [Entered: 09/07/2016 05:04 PM] (2) |
| Sep 6, 2016 | 11 | Entry of appearance for Alice L. Riechers as of counsel for Appellees Perrigo Company and Perrigo Israel Pharmaceuticals Ltd.. Service: 09/06/2016 by email. [364350] [Alice Riechers] [Entered: 09/06/2016 01:23 PM] (2) |
| Sep 6, 2016 | 12 | Docketing Statement for the Appellees Perrigo Company and Perrigo Israel Pharmaceuticals Ltd.. Service: 09/06/2016 by email. [364357] [Alice Riechers] [Entered: 09/06/2016 01:34 PM] (4) |
| Sep 6, 2016 | 13 | Certificate of Interest for the Appellees Perrigo Company and Perrigo Israel Pharmaceuticals Ltd.. Service: 09/06/2016 by email. [364360] [Alice Riechers] [Entered: 09/06/2016 01:38 PM] (3) |
| Sep 6, 2016 | 14 | Entry of appearance for William A. Rakoczy as principal counsel for Appellees Perrigo Company and Perrigo Israel Pharmaceuticals Ltd.. Service: 09/06/2016 by email. [364372] [William Rakoczy] [Entered: 09/06/2016 01:54 PM] (2) |
| Sep 6, 2016 | 15 | Entry of appearance for Anthony J. Fitzpatrick as principal counsel for Appellee Amneal Pharmaceuticals LLC. Service: 09/06/2016 by email. [364500] [Anthony Fitzpatrick] [Entered: 09/06/2016 05:04 PM] (2) |
| Sep 6, 2016 | 16 | Entry of appearance for Christopher S. Kroon as of counsel for Appellee Amneal Pharmaceuticals LLC. Service: 09/06/2016 by email. [364502] [Anthony Fitzpatrick] [Entered: 09/06/2016 05:06 PM] (2) |
| Sep 6, 2016 | 17 | Certificate of Interest for the Appellee Amneal Pharmaceuticals LLC. Service: 09/06/2016 by email. [364504] [Anthony Fitzpatrick] [Entered: 09/06/2016 05:07 PM] (2) |
| Sep 6, 2016 | 18 | Docketing Statement for the Appellee Amneal Pharmaceuticals LLC. Service: 09/06/2016 by email. [364540] [Anthony Fitzpatrick] [Entered: 09/06/2016 06:34 PM] (5) |
| Sep 6, 2016 | 19 | Entry of appearance for Vincent L. Capuano as of counsel for Appellee Amneal Pharmaceuticals LLC. Service: 09/06/2016 by email. [364542] [Anthony Fitzpatrick] [Entered: 09/06/2016 06:35 PM] (2) |
| Aug 31, 2016 | 4 | NOTICE OF DEFICIENCY: The attorney entry of appearance Document No. [3] filed by Appellees Lupin Pharmaceuticals, Inc. and Lupin Ltd. in 16-2555 is without a proper/complete proof of service and therefore cannot be accepted for filing at this time. You are being afforded the opportunity to correct the deficiency. At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [363227] [JCA] [Entered: 08/31/2016 08:33 AM] (0) |
| Aug 31, 2016 | 5 | Corrected Entry of appearance for David B. Abramowitz as of counsel for Appellees Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 08/31/2016 by email, clerk. [363310] [David Abramowitz] [Entered: 08/31/2016 10:21 AM] (2) |
| Aug 31, 2016 | 6 | Entry of appearance for Hugh S. Balsam as of counsel for Appellees Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 08/31/2016 by email. [363313] [Hugh Balsam] [Entered: 08/31/2016 10:27 AM] (2) |
| Aug 31, 2016 | 7 | Certificate of Interest for the Appellees Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 08/31/2016 by email. [363390] [Keith Parr] [Entered: 08/31/2016 12:47 PM] (2) |
| Aug 31, 2016 | 8 | Docketing Statement for the Appellees Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 08/31/2016 by email. [363392] [Keith Parr] [Entered: 08/31/2016 12:49 PM] (5) |
| Aug 31, 2016 | 9 | Entry of appearance for Nina J. Vachhani as of counsel for Appellees Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 08/31/2016 by email. [363525] [Nina Vachhani] [Entered: 08/31/2016 04:19 PM] (2) |
| Aug 31, 2016 | 10 | Entry of appearance for Carolyn A. Blessing as of counsel for Appellees Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 08/31/2016 by email. [363537] [Carolyn Blessing] [Entered: 08/31/2016 05:35 PM] (2) |
| Aug 30, 2016 | 2 | Entry of appearance for Keith D. Parr as principal counsel for Appellees Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 08/30/2016 by email. [363151] [Keith Parr] [Entered: 08/30/2016 04:38 PM] (2) |
| Aug 30, 2016 | 3 | Entry of appearance for David B. Abramowitz as of counsel for Appellees Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 08/30/2016 by clerk. [363177] [David Abramowitz] [Entered: 08/30/2016 05:41 PM] (0) |
| Aug 24, 2016 | 1 | Appeal docketed. Received: 08/24/2016. [361626]Entry of Appearance due 09/07/2016. Certificate of Interest is due on 09/07/2016. Docketing Statement due 09/07/2016. Appellant/Petitioner's brief is due 10/24/2016. [JCA] [Entered: 08/24/2016 03:24 PM] (330) |
